Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZE antiemetic study for zolbetuximab with or without bedtime olanzapine pretreatment
jRCTs041250124Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olanzapine in Nausea and Vomiting (2 arms), sponsored by Astellas Pharma. Primary endpoint: Vomiting control rate during first course. Started Nov 2025; status: active, not recruiting.
02
Drugs
olanzapine
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on jRCTs041250124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250124.